DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1098696
Title:
A Novel Prodrug Strategy to Treat Prostate Cancer by Targeting MYC-Driven Nucleotide Biosynthesis
Descriptive Note:
Technical Report,01 Jun 2017,31 May 2019
Corporate Author:
University of California, San Francisco San Francisco United States
Report Date:
2019-09-01
Pagination or Media Count:
10.0
Abstract:
Over the research period, the two central hypotheses were investigated thoroughly testing analogs of ribose-5-phosphate bearing radionuclides for imaging and therapy and testing a prodrug strategy for the delivery and cellular retention of these analogs into diseased prostate cancer cells. Neither could be achieved. The proposed bromine analogs were difficult to synthesize and proved unstable. The prodrug strategy did not liberate the active form necessary for cellular retention. However, through the examination of two goals, a new complimentary approach has been revealed. Furthermore, despite the difficulty with introduction of bromine atoms, fluorine was found to be easily incorporated and stabile, providing a path for the design of a traditional 18F PET imaging tracer for prostate cancer.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
